ASTRO Updates Guidelines on Partial Breast Irradiation for Early Invasive Cancer
(MedPage Today) -- The American Society for Radiation Oncology (ASTRO) updated their guidelines on partial breast irradiation (PBI) for patients with early-stage invasive breast cancer or ductal carcinoma in situ (DCIS).
These new guidelines take... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 16, 2023 Category: Hematology Source Type: news
Road to RSNA 2023: Molecular Imaging
This is just the third year that RSNA has offered a dedicated track on nuclear medicine and molecular imaging, with eight scientific sessions covering research in prostate cancer imaging, breast cancer, cardiovascular and pulmonary imaging, and more. There will be also 30 educational courses and 14 poster sessions. Notably, this is the first year a scientific session is being offered that covers advances in AI in nuclear medicine. Presentations on PET imaging in prostate cancer – an approach that is witnessing widespread adoption – include an array of studies on prostate-specific membrane antigen (PSMA)-based radiotrac...
Source: AuntMinnie.com Headlines - November 15, 2023 Category: Radiology Authors: Will Morton Tags: 2023 2023 Molecular Imaging Preview Source Type: news
F-18 fluciclovine vs. Ga-68 PSMA: Which tracer is superior in metastatic breast cancer?
Monday, November 27 | 8:40 a.m.-8:50 a.m. | M1-SSNMMI02-5 | Room E350F-18 fluciclovine PET/CT imaging results in greater metastases detection in women with invasive lobular carcinoma (ILC) of the breast than gallium-68 (Ga-68) prostate-specific membrane antigen (PSMA)-PET/CT, while both are superior to conventional imaging, according to this presentation.Presenter Aliza Mushtaq, MD, a postdoc research fellow at Emory University, will discuss a study comparing the use of the two PET radiotracers versus conventional imaging (CT and bone scans) in 20 women with de novo or suspected recurrent ILC.Conventional imaging detected ...
Source: AuntMinnie.com Headlines - November 15, 2023 Category: Radiology Authors: Will Morton Tags: 2023 Molecular Imaging Preview Source Type: news
Road to RSNA 2023: Ultrasound
Ultrasound's utility will be on full display at this year's RSNA annual meeting, showing its merit in a wide variety of clinical applications. Research to be presented at the annual meeting in Chicago will explore the modality's clinical applications in musculoskeletal, pediatric, abdominal, and women's imaging among other areas. This includes advancements in ultrasound in recent years, such as the use of contrast for improved imaging, elastography and color Doppler for assessing complex pathologies, and using imaging data in AI models. Studies will also evaluate ways to further improve the modality's capabilities by rea...
Source: AuntMinnie.com Headlines - November 14, 2023 Category: Radiology Authors: Amerigo Allegretto Tags: 2023 2023 Ultrasound Preview Source Type: news
Roche ’s subcutaneous injection of Tecentriq recommended by the EU’s CHMP for multiple cancer types
If approved, Tecentriq subcutaneous (SC) would be the first injectable PD-(L)1 cancer immunotherapy in the EU, cutting treatment time by approx. 80%1 The CHMP recommended Tecentriq SC for all indications of intravenous (IV) Tecentriq, including certain types of lung, liver, bladder and breast cancer2A majority of healthcare professionals surveyed in the IMscin001 study found that the SC formulation is easy to administer and could save time compared with IV1Basel, 14 November 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency ’s Committee for Medicinal Products for Human Use (C...
Source: Roche Investor Update - November 14, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s subcutaneous injection of Tecentriq recommended by the EU’s CHMP for multiple cancer types
If approved, Tecentriq subcutaneous (SC) would be the first injectable PD-(L)1 cancer immunotherapy in the EU, cutting treatment time by approx. 80%1 The CHMP recommended Tecentriq SC for all indications of intravenous (IV) Tecentriq, including certain types of lung, liver, bladder and breast cancer2A majority of healthcare professionals surveyed in the IMscin001 study found that the SC formulation is easy to administer and could save time compared with IV1Basel, 14 November 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency ’s Committee for Medicinal Products for Human Use (C...
Source: Roche Media News - November 14, 2023 Category: Pharmaceuticals Source Type: news
Recombined CEM images effective for depicting palpable breast lesions
When it comes to working up palpable breast abnormalities with contrast-enhanced mammography (CEM), recombined images better depict the lesion than low-energy ones, research published November 8 in Academic Radiology has found.The findings shed light on a condition that, although is most commonly benign, can also can be a common presenting symptom of breast cancer, wrote a team led by Tali Amir, MD, of Memorial Sloan Kettering Cancer Center in New York City."As such, a thorough work-up [of palpable breast lesions] to exclude carcinoma must always be performed," the group noted.CEM is a promising technology for this applica...
Source: AuntMinnie.com Headlines - November 13, 2023 Category: Radiology Authors: Kate Madden Yee Tags: Subspecialties Breast Imaging Source Type: news
Mammography-based nomogram predicts breast microcalcifications
A mammography-based radiomic nomogram could be useful in predicting risk of malignancy in suspicious breast microcalcifications, according to research published November 7 in Academic Radiology.
A team led by Yusi Chen from the Second Affiliated Hospital of Harbin Medical University in China found that the nomogram, which combined radiomic scoring with clinical factors, achieved a high area under the curve (AUC) value in a validation set of patients with breast microcalcifications.
“The combined model could be considered as a potential imaging marker to predict malignant risk,” Chen and colleagues wrote.
Differentia...
Source: AuntMinnie.com Headlines - November 8, 2023 Category: Radiology Authors: Amerigo Allegretto Tags: Subspecialties Advanced Visualization Breast Imaging Source Type: news
PET predicts chemotherapy responses in breast cancer patients
PET/CT with gallium-68 (Ga-68) FAPI radiotracer can predict responses to neoadjuvant chemotherapy in breast cancer patients, according to a study published November 2 in the Journal of Nuclear Medicine. A team in Fuzhou, China, found that Ga-68 FAPI uptake on early PET/CT scans during chemotherapy indicated which patients were most likely to experience complete responses. This information can have a major impact on how patients are guided through treatment, according to the authors.“Ga-68 FAPI-PET/CT parameters can rapidly provide feedback on tumor changes after only two cycles of chemotherapy,” wrote first author Ling...
Source: AuntMinnie.com Headlines - November 8, 2023 Category: Radiology Authors: Will Morton Tags: Clinical News Subspecialties Molecular Imaging Nuclear Medicine Breast Imaging Source Type: news
Beyond BRCA1/2: Pinpointing the risk of inherited breast cancer genes
Immunohistochemistry for HER2 shows positive membrane staining in this infiltrating ductal carcinoma. At the molecular level, breast cancer is typically broken down into four major subtypes — triple-negative, HER2-positive, luminal A and luminal B — each with different degrees of aggressiveness and responses to treatment. Risk can be a complicated and confounding concept, particularly when it comes to life-or-death situations like cancer. The discovery of the BRCA1 and BRCA2 genes in the 1990s enabled many… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - October 28, 2023 Category: Databases & Libraries Source Type: news
7 ways to reduce healthcare disparities in radiology
Healthcare disparities continue to plague medical imaging, but there are concrete measures radiologists can take to mitigate them, according to a paper published on October 12 in RadioGraphics."Radiologists and radiology practices can become active partners in efforts to assist patients along their imaging journey and overcome existing barriers to equitable cancer screening care for traditionally marginalized populations," wrote a group led by Peter Abraham, MD, of the University of California, San Diego.Avoidable differences in disease burden and outcomes that socially disadvantaged individuals may experience manifest in ...
Source: AuntMinnie.com Headlines - October 16, 2023 Category: Radiology Authors: Kate Madden Yee Tags: Practice Management Source Type: news
Lunit to showcase AI research at ESMO 2023
AI developer Lunit will present nine studies featuring the company's AI pathology technology at the upcoming European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain, being held October 20 to 24, 2023.The abstracts will cover a variety of areas and include the following:AI for prediction of multiple druggable mutations in non-small cell lung cancer from H&E stained imagesLunit Scope IO for distinguishing mismatch repair deficiency from mismatch repair proficiency colon cancers by analyzing features in whole slide imagesAI investigating the efficacy and safety of avelumab plus gemcitabine in leiomyosarcom...
Source: AuntMinnie.com Headlines - October 10, 2023 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Source Type: news
DBT-detected lobular neoplasia shows low upgrade rate
Surveillance could be a preferred management strategy for lobular neoplasi...Read more on AuntMinnie.comRelated Reading:
Breast MRI uptake is low among women at high breast cancer risk
Abbreviated MRI shows promise, CEM has tradeoffs in breast imaging
AI shows perfect performance in invasive lobular carcinoma
CEM on par with breast MRI in lobular breast cancer staging
SBI: The presence of LCIS indicates increased breast cancer risk (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 31, 2023 Category: Radiology Source Type: news
Roche ’s Tecentriq becomes the first subcutaneous anti-PD-(L)1 cancer immunotherapy available to patients in Great Britain, reducing treatment time to just minutes
Tecentriq subcutaneous (SC) is now approved in Great Britain for all indications of intravenousTecentriq, including certain types of lung, bladder, breast and liver cancer, offering a faster, more convenient option to receive treatmentAdministered under the skin within approx. seven minutes,Tecentriq SC saves time for patients and helps conserve resources in healthcare systems1Evaluations by the FDA, EMA and other health authorities globally are ongoingBasel, 29 August 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Tecentriq ® SC (atezolizumab) has been approved by the Medicines and Healthcare products Reg...
Source: Roche Investor Update - August 29, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s Tecentriq becomes the first subcutaneous anti-PD-(L)1 cancer immunotherapy available to patients in Great Britain, reducing treatment time to just minutes
Tecentriq subcutaneous (SC) is now approved in Great Britain for all indications of intravenousTecentriq, including certain types of lung, bladder, breast and liver cancer, offering a faster, more convenient option to receive treatmentAdministered under the skin within approx. seven minutes,Tecentriq SC saves time for patients and helps conserve resources in healthcare systems1Evaluations by the FDA, EMA and other health authorities globally are ongoingBasel, 29 August 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Tecentriq ® SC (atezolizumab) has been approved by the Medicines and Healthcare products Reg...
Source: Roche Media News - August 29, 2023 Category: Pharmaceuticals Source Type: news
